Molecular Formula | C17H14N2O3 |
Molar Mass | 294.3 |
Density | 1.337 |
Melting Point | 215°C(lit.) |
Boling Point | 615.2±55.0 °C(Predicted) |
Solubility | DMSO:58 mg/mL (197.07 mM);Water Insoluble;Ethanol :6 mg/mL (20.38 mM) |
Appearance | Yellow powder |
Color | yellow |
pKa | 8.75±0.10(Predicted) |
Storage Condition | -20°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO, DMF, or ethanol may be stored at -20°C for up to 1 month. |
MDL | MFCD00236452 |
Use | This product is for scientific research only and shall not be used for other purposes. |
In vitro study | AG-490 inhibited EGF-dependent HER 14 cell proliferation with an IC50 of 3.5 μm. Consistent with JAK2, which specifically acts on pre-B-cell acute leukemia (ALL) cells to inhibit constitutive activation, 5 μm AG-490 almost completely inhibited the growth of ALL cells by inducing programmed cell death, and the normal hematopoietic function will not cause harmful effects. AG-490 does not inhibit Lck, Lyn, Btk, Syk, and Src activation. AG-490 (60-100 μm) inhibits Stat3 by inhibiting the activity of JAK3 and STAT5a/B. AG-490 potently inhibits human T cell growth regulated by IL-2 with an IC50 of 25 μm. Although 5 μm AG-490 alone had no effect on FDrv210H cell proliferation, AG-490 could synergize STI571 while potentiating STI571 inhibition p210AG-490 acts on MOPC, MPC11, and S194 cells, significantly Inhibiting Stat3 constitutive activation, leading to significant apoptosis, in a dose-dependent manner. AG-490 (100 μm) inhibited Akt phosphorylation, inhibited nuclear factor-kappa B activation, and activated GSK-3β, resulting in a c-Myc reduction. AG-490 (50 μm) induced apoptosis in BaF3 cells expressing Bcr-Abl mutant T315I and E255K anti-Imatinib. 30 μm AG-490 inhibited not only Epo-induced wild-type JAK2 phosphorylation, but also constitutive JAK2 V617F mutant phosphorylation. AG-490 effectively inhibits JAK 2 V617F in BaF3 cells Mutation-induced cytokine-independent cell growth. |
In vivo study | AG-490 treatment significantly reduced CD45 in vivo, and AG-490 treatment caused apoptosis of mouse myeloma cells, but did not inhibit IL-12-induced macrophage activation and IFN-γ production. Consistent with the inhibition of JAK2 V617F mutation activity in vitro, AG-490 treated with 0.5 mg per day for 10 days in nude mice efficiently inhibited JAK2 V617F mutation-induced tumor formation and tumor cell invasion. |
Risk Codes | R36/37/38 - Irritating to eyes, respiratory system and skin. R50 - Very Toxic to aquatic organisms R25 - Toxic if swallowed |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36 - Wear suitable protective clothing. S61 - Avoid release to the environment. Refer to special instructions / safety data sheets. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
UN IDs | UN2811 - class 6.1 - PG 3 - EHS - Toxic solids, organic, n.o.s., HI: all |
WGK Germany | 1 |
RTECS | UC6316197 |
HS Code | 29269090 |
Hazard Class | 6.1 |
Packing Group | III |
biological activity | AG-490 (Tyrphostin B42, Zinc02557947) is an EGFR inhibitor. in cell-free test, IC50 is 0.1 μM, which is 135 times more selective than ErbB2, and also has inhibitory effect on JAK2, Lck,Lyn,Btk, syk and Src had no inhibitory activity. |
target | TargetValue JAK2 (V617F) () EGFR (Cell-free say) 0.1 μM |
Target | Value |
JAK2 (V617F) () | |
EGFR (Cell-free assay) | 0.1 μM |
in vitro study | AG-490 inhibited EGF-dependent HER 14 cell proliferation with IC50 of 3.5 μM. Consistent with JAK2, which specifically acts on pre-B cell acute leukemia (ALL) cells to inhibit constitutive activation, 5 μM AG-490 almost completely inhibits the growth of all ALL cells by inducing programmed cell death, without causing harmful effects on normal hematopoietic function. AG-490 does not inhibit Lck, Lyn, Btk, Syk, and Src activation. AG-490 (60-100 μM) inhibits Stat3 by inhibiting JAK3 and STAT5a/B. AG-490 effectively inhibited IL-2-regulated human T cell growth with an IC50 of 25 μM. Although 5 μM AG-490 alone has no effect on FDrv210H cell proliferation, AG-490 can cooperate with STI571 to enhance STI571 inhibitory p210AG-490 on MOPC, MPC11, and S194 cells, significantly inhibiting Stat3 constitutive activation, leading to significant apoptosis, which is dose-dependent. AG-490 (100 μM) inhibits Akt phosphorylation, inhibits nuclear factor-κB activation, and activates GSK-3β, resulting in reduced c-Myc. AG-490 (50 μM) can induce apoptosis of anti-Imatinib BaF3 cells expressing Bcr-Abl mutant T315I and E255K. 30 μM AG-490 not only inhibited Epo-induced wild-type JAK2 phosphorylation, but also inhibited constitutive JAK2 V617F mutant phosphorylation. AG-490 acts on BaF3 cells and effectively inhibits cytokine-independent cell growth induced by JAK 2 V617F mutation. |
in vivo study | AG-490 treatment greatly reduced CD45 in vivo, AG-490 treatment, causing apoptosis of mouse myeloma cells, but did not inhibit IL-12-induced macrophage activation and IFN-γ production. Consistent with inhibiting JAK2 V617F mutation activity in vitro, AG-490 treated nude mice at 0.5 mg per day for 10 days efficiently inhibited JAK2 V617F mutation-induced tumor formation and tumor cell invasion. |